The impact of COVID-19 monoclonal antibodies on clinical outcomes : A retrospective cohort study
© American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
PURPOSE: Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis.
METHODS: A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19-specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis.
RESULTS: A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 79(2022), 24 vom: 05. Dez., Seite 2222-2229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
R Nagler, Arielle [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajhp/zxac295 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347577636 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347577636 | ||
| 003 | DE-627 | ||
| 005 | 20231226034146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajhp/zxac295 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347577636 | ||
| 035 | |a (NLM)36242772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a R Nagler, Arielle |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of COVID-19 monoclonal antibodies on clinical outcomes |b A retrospective cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a PURPOSE: Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis | ||
| 520 | |a METHODS: A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19-specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis | ||
| 520 | |a RESULTS: A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a bamlanivimab | |
| 650 | 4 | |a casirivimab | |
| 650 | 4 | |a imdevimab | |
| 650 | 4 | |a monoclonal | |
| 650 | 7 | |a imdevimab |2 NLM | |
| 650 | 7 | |a 2Z3DQD2JHM |2 NLM | |
| 650 | 7 | |a etesevimab |2 NLM | |
| 650 | 7 | |a N7Q9NLF11I |2 NLM | |
| 650 | 7 | |a casirivimab |2 NLM | |
| 650 | 7 | |a J0FI6WE1QN |2 NLM | |
| 650 | 7 | |a bamlanivimab |2 NLM | |
| 650 | 7 | |a 45I6OFJ8QH |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Horwitz, Leora I |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Petrilli, Christopher M |e verfasserin |4 aut | |
| 700 | 1 | |a Iturrate, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Lighter, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bosworth, Brian P |e verfasserin |4 aut | |
| 700 | 1 | |a Polsky, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Volpicelli, Frank M |e verfasserin |4 aut | |
| 700 | 1 | |a Dapkins, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanathan, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a François, Fritz |e verfasserin |4 aut | |
| 700 | 1 | |a Kalkut, Gary |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists |d 1995 |g 79(2022), 24 vom: 05. Dez., Seite 2222-2229 |w (DE-627)NLM075145952 |x 1535-2900 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2022 |g number:24 |g day:05 |g month:12 |g pages:2222-2229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajhp/zxac295 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2022 |e 24 |b 05 |c 12 |h 2222-2229 | ||